



**CERTIFICATE OF MAILING**  
37 C.F.R. 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date below:

6-20-2006

*Bonnie K. Knutson*

Date

Signature

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: §  
**Robert F. Garry** § Group Art Unit: **1648**  
**Srikanta Dash** §  
**David H. Coy** § Examiner:  
**Jane A. McKeating** §  
Serial No.: **10/532,480** ✓ § Atty. Dkt. No.: **12920.0014.PCUS00**  
Filed: **April 22, 2005** § § 371 US national stage of  
Confirmation No.: **8283** § PCT/US2003/035666  
**FLAVIVIRUS FUSION INHIBITORS** §  
§  
§  
§

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Supplemental Information Disclosure Statement be entered and the documents listed on attached forms PTO/SB/08A and PTO/SB/08B be considered by the Examiner and

IDS

made of record in the current application. Supplied herewith are copies of references B1-B4, C13-C21, and a copy of a Partial Search Report for a related international application.

In accordance with 37 C.F.R. § 1.97(g) and (h), this Supplemental Information Disclosure Statement is not to be construed as a representation that a search has been made, or as an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

It is believed that this paper is being filed before an Office Action on the merits of the application has been sent; therefore no fee is believed to be due. However, should any fees be required for any reason in connection with this paper, the Commissioner is authorized to deduct said fees from Howrey Deposit Account No. 08-3038/12920.0014.PCUS00.

Respectfully submitted,



Dennis R. Chesire, Ph.D.  
Reg. No. 57,452  
Agent for Assignee  
THE ADMINISTRATORS OF THE  
TULANE EDUCATIONAL FUND

Customer No. 23369  
HOWREY LLP  
1111 Louisiana, 25<sup>th</sup> Floor  
Houston, Texas 77002  
(713) 654-7678 (direct)

Date: June 19, 2006

IDS



INFORMATION DISCLOSURE STATEMENT BY APPLICANT <small>(Use as many sheets as necessary)</small>				<b>Complete if Known</b>	
Sheet	1	of	1	Application Number	10/532,480
				Filing Date	April 22, 2005
				First Named Inventor	Robert F. Garry
				Art Unit	1648
				Examiner Name	
				Attorney Docket Number	12920.0014.PCUS00

<b>U. S. PATENT DOCUMENTS</b>					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
	A3	US- 5,610,009	05/11/97	Watanabe et al	
	A4	US- 4,810,492	03/07/89	Fujita et al	
		US-			


<b>FOREIGN PATENT DOCUMENTS</b>					
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)			
	B1	WO 01/51673 A1	07-19-2001	Trimeris, Inc.	
	B2	WO 00/75337 A1	12-14-2000	Bukh et al.	
	B3	EP 0 982 402 A1	03-01-2000	Stichting Instituut voor Dierhouderij en Diergezondheid	
	B4	WO 99/55366	11-04-1999	Washington University	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



JUN 23 2006

PTO/SB/08B (07-05)

Approved for use through 06/30/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO TRADEMARK OFFICE				Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				Application Number	10/532,480
(Use as many sheets as necessary)				Filing Date	April 22, 2005
				First Named Inventor	Robert F. Garry
				Art Unit	1648
				Examiner Name	
Sheet	1	of	2	Attorney Docket Number	12920.0014.PCUS00

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher city and/or country where published			T <sup>2</sup>
	C13	VOLKOVA, T.D.; ET AL, "The Protein E 98-113 Sequence as the Fusion Site of Tick-Borne Encephalitis Virus with a Cellular Membrane", Bioorganicheskaya Khimiya (1998), Vol. 24, No. 9, p. 676-681. (Abstract Only)			
	C14	VOLKOVA, T.D., ET AL, "A Monoclonal Antibody That Recognizes The Predicted Tick-Borne Encephalitis Virus E Protein Fusion Sequence Blocks Fusion", Archives of Virology (1999), Vol. 144, p. 1035-1039.			
	C15	ALLISON, S.L., ET AL, "Mutational Evidence for an Internal Fusion Peptide in Flavivirus Envelope Protein E", Journal of Virology (2001), Vol. 75, No. 9, p. 4268-4275.			
	C16	STIASNY, K., ET AL, "Membrane Interactions of the Tick-Borne Encephalitis Virus Fusion Protein E at Low pH", Journal of Virology (2002), Vol. 76, No. 8, p. 3784-3790.			
	C17	CRILL, W.D., ET AL, "Monoclonal Antibodies That Bind to Domain III of Dengue Virus E Glycoprotein Are the Most Efficient Blockers of Virus Adsorption to Vero Cells", Journal of Virology (2001), Vol. 75, No. 16, p. 7769-7773.			
	C18	BHARDWAJ, S., ET AL, "Biophysical Characterization and Vector-Specific Antagonist Activity of Domain III of the Tick-Borne Flavivirus Envelope Protein", Journal of Virology (2001), Vol. 75, No. 8, p. 4002-4007.			
	C19	REY, F.A., ET AL, "The Envelope Glycoprotein From Tick-Borne Encephalitis Virus at 2 Å Resolution", Nature (1995), Vol. 375, p. 291-298.			

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

DM\_US18356684.v1

Substitute for form 1449B/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>				Application Number	10/532,480
				Filing Date	April 22, 2005
				First Named Inventor	Robert F. Garry
				Art Unit	1648
				Examiner Name	
Sheet	2	of	2	Attorney Docket Number	12920.0014.PCUS00

<b>NON PATENT LITERATURE DOCUMENTS</b>				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher city and/or country where published		
	C20	HUNG, S., ET AL, "Analysis of the Steps Involved in Dengue Virus Entry into Host Cells", <i>Virology</i> (1999), Vol. 257, p. 156-167.		
	C21	SHAI, Y., "Functional Domains within Fusion Proteins: Prospectives for Development of Peptide Inhibitors of Viral Cell Fusion, <i>Bioscience Reports</i> (2000), Vol. 20, No. 6, p. 535-555.		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.